Posters

Experience of the visual outcome following aberration-free LASEK enhancements in patients with refractive error after pseudophakic surgery

Poster Details

First Author: S.Mughal UK

Co Author(s):                        

Abstract Details

Purpose:

To assess the visual and refractive outcomes following LASEK enhancements in 41 eyes to treat residual or surgically induced refractive error after pseudophakic surgery.

Setting:

One certified and experienced corneal laser surgeon treating patients between April 2012 and July 2014 in the Optimax Laser Clinics in UK.

Methods:

This was a retrospective analysis of 41 eyes from 38 patients who had LASEK enhancement were divided into four groups: monofocal non-toric monofocal non-toric multifocal non-toric and multifocal toric. The mean age of the patients was 55.1 years and 83% of eyes had YAG posterior capsulotomy prior to LASEK enhancement. The aspheric aberration-free profile of the ORK-CAM software was used and patients were mainly treated on the SCHWIND AMARIS platform with laser repetition rate of 750Hz and tracking employed in all cases. Laser ablation was centred on the pupil entrance.

Results:

For all the groups combined, the manifest mean sphere was reduced from +0.47 ± 0.8 D (range: -1.50 to +1.75) to +0.07 ± 0.27 D (range: -0.75 to +0.75). The manifest mean cylinder was reduced from -1.18 ± 0.63 D (range: 0 to -2.50) to -0.23 ± 0.26 D (range: 0 to -0.75). The preoperative manifest mean spherical equivalent reduced from -0.12 ± 0.76 D to -0.05 ± 0.30 D. In 97.5% of eyes, the uncorrected vision was 20/25 or better following LASEK enhancement. No patient lost 2 or more lines of best corrected vision.

Conclusions:

The aberration-free ablation profile provides effective and safe outcomes for treating residual or surgically induced refractive error following pseudophakic surgery. No retreatments were required to be performed. YAG posterior capsulotomy would appear to be a main pre-requisite prior to LASEK in order to improve the accuracy of manifest refraction critical in multifocal patients.

Financial Disclosure:

NONE